HomeProductsBioactive CompoundsGPCR & G Protein TargetsEndothelin ReceptorAvosentan
Chemical structure of CAS 290815-26-8

Avosentan

CAS No.290815-26-8
MDL No.MFCD23843806
MFC23H21N5O5S
MW479.50
InChI KeyYBWLTKFZAOSWSM-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.290815-26-8
Product NameAvosentan

Biological Targets

EDNRA

Associated Conditions

diabetic nephropathy
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Diabetes • Vol. 59, Issue 12 • 2010
PMID: 20823099PMC: PMC2992783DOI: 10.2337/db10-0195

Avosentan for overt diabetic nephropathy.

Journal of the American Society of Nephrology : JASN • Vol. 21, Issue 3 • 2010
PMID: 20167702PMC: PMC2831858DOI: 10.1681/ASN.2009060593

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Diabetologia • Vol. 53, Issue 1 • 2010
PMID: 19862499DOI: 10.1007/s00125-009-1540-3

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.

American journal of physiology. Renal physiology • Vol. 297, Issue 5 • 2009
PMID: 19675181DOI: 10.1152/ajprenal.00340.2009

Documentation

Similar Products